Previous studies on allosteric interactions at muscarinic receptors have often focused on ligand-receptor binding interactions, because ligand binding seemed to reflect functional consequences. The prototypal allosteric agent alcuronium is known to bind with similar affinity to the M 2 subtype of muscarinic acetylcholine receptors whether or not the receptors are occupied by the agonist pilocarpine. To determine allosteric modulation of receptor signaling by alcuronium, the effects of pilocarpine were measured in contracting guinea pig left atria and on G-protein coupling in M 2 -transfected Chinese hamster ovary (CHO) cell membranes. Alcuronium dose-dependently suppressed pilocarpine-induced reduction of isometric contraction force in atria (pIC 50, Alc ϭ 5.63) without any effect on the EC 50 of pilocarpine, consistent with an allosteric mechanism. In contrast, alcuronium shifted the concentration-effect curve of the agonist oxotremorine M to the right without affecting the maximal effect, in a formally competitive manner (pK A, Alc ϭ 5.54). If pilocarpine remained receptor bound in the presence of alcuronium, this indicates that pilocarpine can no longer act as an agonist. In support of this hypothesis, pilocarpine acted as a competitive antagonist against oxotremorine M in the presence of 10 M alcuronium. Measuring guanosine 5Ј-O-(3-[ 
without affecting the maximal effect, in a formally competitive manner (pK A, Alc ϭ 5.54). If pilocarpine remained receptor bound in the presence of alcuronium, this indicates that pilocarpine can no longer act as an agonist. In support of this hypothesis, pilocarpine acted as a competitive antagonist against oxotremorine M in the presence of 10 M alcuronium. Measuring guanosine 5Ј-O- (3-[ The G protein-coupled muscarinic acetylcholine receptors are subject to allosteric modulation (Tuček and Proška, 1995; Ellis, 1997; Christopoulos et al., 1998; Holzgrabe and Mohr, 1998) . Initial evidence from experiments with isolated contracting heart preparations demonstrated that gallamine (Clark and Mitchelson, 1976 ) and alkane-bis-ammoniumtype compounds (Lü llmann et al., 1969; Mitchelson, 1975) acted as antagonists with a ceiling effect at high concentrations. Subsequent ligand-receptor binding studies with [ (Stockton et al., 1983; Jepsen et al., 1988; Choo and Mitchelson, 1989) . Allosteric agents retard the dissociation of [ 3 H]NMS, indicating formation of a ternary complex with the radioligand-occupied receptor. In addition, muscarinic allosteric agents interact with unliganded receptors and, thereby, inhibit the association of conventional, orthosteric ligands (Kostenis and Mohr, 1996; Schröter et al., 2000) .
Hence, allosteric modulation of association and dissociation has opposite effects on equilibrium binding of the orthosteric ligand. Whereas gallamine and many alkane-bis-ammonium agents reduce [ 3 H]NMS binding, alcuronium elevates binding of [ 3 H]NMS to cardiac muscarinic M 2 receptors (Tuček et al., 1990) because of pronounced inhibition of [ 3 H]NMS-receptor dissociation (Schröter et al., 2000) . These findings prompted a search for allosteric enhancers of acetylcholine binding. Although alcuronium fails to elevate acetylcholine binding at any of the five muscarinic subtypes (Jakubík et al., 1997) , brucine derivatives with a structure similar to onehalf of the alcuronium molecule enhance the binding and action of acetylcholine . Among the five subtypes, acetylcholine-occupied M 2 receptors seem to be rather insensitive to this effect of the brucine analogs .
Muscarinic allosteric actions depend on the allosteric agent, the orthosteric ligand, and the muscarinic receptor subtype (Lee and El-Fakahany, 1988; Ellis et al., 1991) . Jakubík et al. (1997) investigated the effects of alcuronium, The work was supported by grants provided by the Deutsche Forschungsgemeinschaft (to K.M.) and by the German Academic Exchange Service, DAAD (to N.E.). brucine, and structurally related compounds on the equilibrium binding of 12 agonists in cloned M 1 -M 4 receptors. Among the allosteric agents, alcuronium had, by far, the highest affinity for M 2 receptors. When pilocarpine was bound to the M 2 receptors, the affinity of alcuronium was even somewhat increased. The factor of cooperativity (Ehlert, 1988a) between alcuronium and pilocarpine, ␤ ϭ 0.37 (Jakubík et al., 1997) , means a 2.7-fold higher affinity of alcuronium for pilocarpine-occupied M 2 receptors compared with free receptors. Therefore, we selected pilocarpine-alcuronium interactions to investigate the functional consequences of ternary complex formation in an intact M 2 -containing tissue, i.e., contracting guinea pig atria. Alcuronium unexpectedly suppressed the agonist effects of pilocarpine and even caused pilocarpine to behave like a muscarinic antagonist. We confirmed these unique functional properties of a muscarinic allosteric agent at the level of receptor-G protein coupling by measuring pilocarpine stimulation of [
35 S]GTP␥S binding to Chinese hamster ovary (CHO) membranes expressing M 2 receptors. The combined results demonstrate for the first time that a muscarinic allosteric agent can modulate the intrinsic efficacy of an orthosteric muscarinic receptor ligand.
Materials and Methods
Organ Bath Experiments. The procedure to measure the actions of muscarinic agents in contracting guinea pig atria has been described previously (Trä nkle et al., 1998) . Left atria were mounted in organ baths containing 20 ml of oxygenated Tyrode's solution (136.9 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl 2 , 1.05 mM MgCl 2 , 11.9 mM NaHCO 3 , 0.21 mM NaH 2 PO 4 , and 5.5 mM dextrose; 95% O 2 /5% CO 2 ; pH 7.3; 32°C). The preparations were preloaded with 5 millinewton and electrically stimulated via platinum contact electrodes at 3 Hz with rectangular pulses of 5-ms duration. The voltage was 1.5-fold over the threshold of excitation amounting to about 2 V. Contraction force (CF) was recorded isometrically. After an equilibration period of 60 min (CF ϭ 5.5 Ϯ 0.1 millinewton, mean Ϯ standard error, n ϭ 234 atria), a cumulative concentration/effect curve for the negative inotropic action of the agonist under study was recorded. Each agonist concentration was applied for 10 min, a period sufficient to obtain equilibrium effects. Contraction force was expressed as the percentage of the value found at the end of the equilibration period. The agonist was removed from the organ bath over a period of 30 min by replacing the Tyrode's solution with fresh solution every 10 min. Thereafter, the preparation was preincubated with the allosteric test compound for 60 min before another agonist concentration/effect curve was measured in the presence of the allosteric compound. Contraction force was expressed as the percentage of the value at the end of the preincubation period with the allosteric agent. The agonist was washed out using Tyrode's solution still containing the allosteric agent in the concentration as before. After 30 min of washout, the concentration of the allosteric agent was increased, and, after a preincubation phase of 60 min, another concentration/effect curve of the agonist was measured. Modifications of this protocol are mentioned under Results.
Cell Culture and Membrane Preparation. Cell culture and [ 35 S]GTP␥S binding experiments were carried out in a similar way as described by Burford et al. (1995) . A CHO cell line stably transfected with the human gene for the muscarinic M 2 receptor and wild-type CHO cells were a gift of Prof. Dr. G. Lambrecht (Department of Pharmacology, Biocenter Niederursel, University of Frankfurt/Main, Germany). Cells were cultured at 37°C under humidified air supplemented with 5% CO 2 in Ham's F 12 medium containing 10% fetal calf serum, 100 IU/ml penicillin G, 100 g/ml streptomycin, and 1 mM glutamine. For membrane preparation, cells grown to confluence were treated for 24 h with 5 mM Na-butyrate added to the culture medium before harvesting the cells in a buffer of 10 mM HEPES, 154 mM NaCl, and 0.7 mM EDTA, pH 7.4 at room temperature. The subsequent steps were carried out at 4°C. The cell suspension was centrifuged at 185g (Avanti J25, rotor type JS-7.5; Beckman Instruments, Palo Alto, CA) for 5 min, the supernatant was discarded, the pellet was resuspended in homogenization buffer (10 mM HEPES, 10 mM EDTA, 10 mM NaF, and 10 mM Na 2 P 2 O 7 , pH 7.4), and the first centrifugation step was repeated. The pelleted cells were disrupted using a Polytron homogenizer (PT 10 -35; Kinematica AG, Littau, Switzerland; level 7, six bursts of 5-s duration and intervals of 30 s in between), and the resulting homogenate was centrifuged at 40,000g (Avanti J25, rotor type JA 25.50) for 17 min. After discarding the supernatant, the pellet was resuspended in storage buffer (10 mM HEPES and 0.1 mM EDTA, pH 7.4) and centrifuged again. The membranes were resuspended in storage buffer and stored at Ϫ80°C.
[ 35 S]GTP␥S Binding Experiments. Membranes (100 l, final concentration 150 g of protein/ml) were added to the incubation buffer (900 l; 10 mM HEPES, 100 mM NaCl, and 10 mM MgCl 2 , pH 7.4) containing (final concentrations) 0.07 nM [
35 S]GTP␥S (1250 Ci/mmol), 10 M GDP, and the test compounds at the indicated concentrations. After an incubation period of 60 min at 30°C, the incubation medium was filtered through glass fiber filters (Schleicher & Schü ll, Dassel, Germany), and filter-bound radioactivity was measured by liquid scintillation counting. Jakubík et al. (1997) but without 0.5 mM GTP (136 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 0.2 mM KH 2 PO 4 , 0.8 mM Na 2 HPO 4 , and 10 mM Na-HEPES, pH 7.4, at 25°C). After time periods appropriate to reach binding equilibrium of up to 3 h, the incubation medium was filtered through glass fiber filters (no. 6, Schleicher & Schü ll) followed by two rinses with ice-cold incubation buffer. Filter-bound radioactivity was measured by liquid scintillation counting. Nonspecific binding of [ 3 H]oxotremorine M was determined in the presence of 1 M atropine and amounted to about 20% of the total binding. Data Analysis. Indicated are mean values Ϯ standard error. Unless otherwise indicated concentration/effect curves were fitted to the data by nonlinear regression analysis using the following fourparameter logistic equation
X is the drug concentration; Y is the response. The parameters "Top" and "Bottom" refer to the upper and lower plateau of the sigmoidal curve, respectively. Log EC 50 denotes the log X at the inflection point of the sigmoidal curve, and n H is the slope factor of the curve. Antagonist-induced parallel curve shifts were quantified by agonist dose-ratios DR ϭ EC 50 , test compound /EC 50 , control and analyzed using the equation
pK is the equilibrium dissociation constant of the antagonist and s indicates the slope of the regression line. Binding constants (K D , K X ) were derived from IC 50 values according to DeBlasi et al. (1989) and Cheng and Prusoff (1973) (Ehlert 1988a ) using the equation
where B o is the binding of L in the absence of A; K D and K A denote the equilibrium dissociation constants for the binding of L and of A, respectively, to the free receptor; and ␣ is the factor of cooperativity for the interaction between L and A (e.g. , Ehlert 1988a; Trä nkle et al., 1999) .
, pilocarpine (X), and alcuronium (A) were analyzed on the basis of the ternary complex model according to Jakubík et al. (1997) using the equation
K X is the equilibrium dissociation constant for the binding of pilocarpine (X) to free receptors. The cooperativity between X and A is indicated by the cooperativity factor ␤. Data analysis, graphical presentations and statistical testing were carried out using the software PRISM version 3.0 and INSTAT version 3.0 (GraphPad, San Diego, CA).
Drugs. Oxotremorine M iodide was obtained from Research Biochemicals International (Natick, MA). Pilocarpine hydrochloride, gallamine triethiodide, (Ϯ)-propranolol, hexamethonium bromide, Ham's F12 medium, fetal calf serum, penicillin G, streptomycin, glutamine, and HEPES were purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Na-butyrate was from Acros Organics (Geel, Belgium). 
Results

Drug Effects on the Contraction Force of Guinea Pig
Atria. The concentration/effect curve for the negative inotropic action of pilocarpine as obtained under control conditions is shown in Fig. 1A . The inflection point of the curve was (mean Ϯ standard error, n ϭ 13) pEC 50 ϭ 6.10 Ϯ 0.03; the slope factor was n H ϭ Ϫ1.28 Ϯ 0.12; and the maximal effect of pilocarpine was indicated by the bottom plateau of the curve at CF min ϭ 18 Ϯ 2% of the predrug force of contraction. Repeated measurements of pilocarpine concentration/effect curves in control preparations over intervals of up to 300 min after starting with the first curve revealed that the sensitivity of the preparations to pilocarpine remained stable (data not shown). Alcuronium alone (0.1-100 M) in the preincubation period of 60 min had no effect on the contraction force of the preparations (data not shown). The time course of the negative inotropic action of pilocarpine seemed to be unchanged under the influence of alcuronium. The pilocarpine concentration/effect curve was hardly affected at 0.1 (not shown) and 0.3 M alcuronium. At higher concentrations of alcuronium (Fig. 1A) , the maximal effect of pilocarpine was reduced (one-way ANOVA, P Ͻ 0.0001), whereas the slope factors of the curves (P ϭ 0.298) and the pEC 50 values (P ϭ 0.801) were not different from the respective control values.
The concentration/effect relationship for the alcuroniuminduced elevation of the lower plateaus CF min of the pilocarpine curves is depicted in Fig. 1B . For nonlinear regression analysis, the bottom plateau of the curve was fixed at the control level of 18% (see above). The slope factor was not significantly different from unity and was set to n H ϭ 1; the Ϫlog inflection point of the curve was at pIP ϭ 5.63 Ϯ 0.14 (n ϭ 34 experiments). The upper plateau of the curve (89 Ϯ 8%) remained slightly below 100%, which may be explained by the spontaneous loss of contraction force over the period of 1 h required to record a cumulative concentration/effect curve of pilocarpine. As mentioned below, when starting immediately with a high concentration of pilocarpine (up to 200 M), in the presence of 10 M alcuronium, pilocarpine failed to cause a negative inotropic effect.
The alcuronium-induced attenuation of the maximal effect of pilocarpine was reversible upon washout (data not shown) and was not related to endogenous catecholamines as tested by adding the nonspecific ␤-adrenoceptor blocking drug propranolol at 1 M or the ganglionic blocking agent hexamethonium at 100 M.
We suspected that alcuronium suppressed the intrinsic efficacy of pilocarpine. Thus, pilocarpine should behave like an antagonist against another agonist in the presence of alcuronium. To test this, we chose the agonist oxotremorine M, which is antagonized in a formally competitive fashion by alcuronium in contracting guinea pig atria (Maass et al., 1995) . Evidence for the formation of ternary complexes, as reflected by an inhibition of [ 3 H]oxotremorine M dissociation in cardiac membranes, occurred only at high alcuronium concentrations (100 M) (Maass and Mohr, 1996) . As shown in Fig. 2A , alcuronium induced a parallel rightward shift of the concentration/effect curve of oxotremorine M (parameters of the control curve pEC 50 ϭ 7.92 Ϯ 0.05; n H ϭ Ϫ1.56 Ϯ 0.16; CF min ϭ 7 Ϯ 2%, n ϭ 8). A Schild plot of the data (Fig. 2B ) yielded a slope of unity, indicating a formally (but possibly not topologically) competitive antagonism. The Ϫlog equilibrium dissociation constant of alcuronium binding to free M 2 receptors amounted to pK A ϭ 5.54 Ϯ 0.04, n ϭ 15 and is in line with the value found previously under the same conditions (pA 2 ϭ 5.7, Maass et al., 1995) . In the next set of experiments, concentration/effect curves of oxotremorine M were recorded in the presence of a fixed concentration of 10 M alcuronium and stepwise increased concentrations of pilocarpine. In these experiments (Fig. 3A) , oxotremorine M was first applied alone, then in the presence of alcuronium (preincubation time 1 h), and subsequently in the presence of alcuronium plus one of the indicated concentrations of pilocarpine (preincubation time, 15 min). Alcuronium induced the expected rightward shift of the oxotremorine M curve. In the presence of 10 M alcuronium, addition of pilocarpine alone even at 200 M had no negative inotropic effect (data not shown). The concentration/effect curve of oxotremorine M, however, was shifted to the right in a parallel fashion with increasing concentrations of pilocarpine in the presence of alcuronium (Fig. 3A) . The antagonistic action of pilocarpine against oxotremorine M was evaluated in a Schild plot using the EC 50 of the oxotremorine M curve with alcuronium present and pilocarpine absent as the reference (second curve from the left in Fig. 3A ). As shown in Fig. 3B , the data points fall on a straight line with a slope of unity. Thus, pilocarpine (in the presence of 10 M alcuronium) behaved like a competitive antagonist against oxotremorine M. The Schild plot yielded as the Ϫlog equilibrium dissociation constant for pilocarpine binding in the presence of 10 M alcuronium: pK ϭ 6.18 Ϯ 0.06 (n ϭ 11). The concentration-dependent antagonistic action of pilocarpine indicated that pilocarpine Fig. 3 . A, concentration/effect curves for the negative inotropic action of oxotremorine M under the influence of pilocarpine in the presence of a fixed concentration of alcuronium. Ordinate, isometric force of contraction of the contracting guinea pig left atria as a percentage of the respective value before addition of oxotremorine M. Abscissa, concentration of cumulatively applied oxotremorine M. Data points indicate mean values Ϯ S.E.M. of n ϭ 2 to 10 preparations. Curve fitting was based on a four-parameter logistic function. Slope factors and minimal plateaus did not differ significantly and were set constant with n H ϭ Ϫ1.62 and CF min ϭ 9, respectively. B, Schild plot of the oxotremorine M curve shift induced by pilocarpine in the presence of 10 M alcuronium. Ordinate, dose ratio (DR) ϭ oxotremorine M EC 50 with pilocarpine in the presence of 10 M alcuronium divided by oxotremorine M EC 50 without pilocarpine in the presence 10 M alcuronium. Abscissa, log concentration of pilocarpine in the presence of 10 M alcuronium. Indicated are individual shift factors based on complete concentration/effect curves. Linear regression analysis yielded a line with a slope not different from unity. Fig. 2 . A, negative inotropic action of oxotremorine M in contracting guinea pig left atria in the absence and in the presence of alcuronium at the indicated concentrations. Ordinate, isometric force of contraction as a percentage of the predrug value. Abscissa, concentration of oxotremorine M added to the organ bath in cumulative fashion. Data represent means Ϯ standard error from measurements in n ϭ 2 to 8 preparations. Error bars are not shown when they do not exceed the symbols. Curve fitting based on a four-parameter logistic function. Slope factors and minimal plateaus did not differ significantly and were set constant to n H ϭ Ϫ1.44 and CF min ϭ 8, respectively. B, Schild plot of the oxotremorine M curve shift induced by alcuronium. Ordinate, dose ratio (DR) ϭ oxotremorine M EC 50 in the presence of alcuronium divided by oxotremorine M EC 50 without alcuronium. Abscissa, log concentration of alcuronium. Indicated are individual shift factors based on complete concentration/effect curves. Linear regression analysis yielded a line with a slope not different from unity. (Fig. 4A) ; E max was 172 Ϯ 3%, the half-maximal effect occurred at pEC 50 ϭ 5.48 Ϯ 0.12 (slope factor n H ϭ 0.68 Ϯ 0.10, n ϭ 3 experiments in up to quadruplicate determinations). The effect of pilocarpine was then measured in the presence of 3 M (n ϭ 3 experiments in duplicate determinations) and 10 M (n ϭ 2 experiments in duplicate determinations; Fig. 4A ) alcuronium. Alcuronium alone significantly suppressed basal [ 35 S]GTP␥S binding (one-way ANOVA, p Ͻ 0.0001). In the presence of 3 M alcuronium, both the inflection point of the pilocarpine curve, pEC 50 ϭ 5.43 Ϯ 0.16, and the slope factor of the curve, n H ϭ 0.85 Ϯ 0.23, were unchanged compared with the pilocarpine curve recorded under control conditions (unpaired t test, two-tailed, p Ͼ 0.05). The maximal effect with 10 Ϫ2 M pilocarpine, however, was significantly attenuated by alcuronium (one-way ANOVA, p Ͻ 0.0001). In the presence of 10 M alcuronium, pilocarpine was inactive.
Alcuronium Hilf and Jakobs (1992) : pIC 50 8.7. There was no difference between the lower plateaus of the curves for alcuronium and atropine, respectively (E max, alcuronium ϭ 64 Ϯ 2% and E max, atropine ϭ 64 Ϯ 1%). The stimulation of [ 35 S]GTP␥S binding by 10 Ϫ2 M pilocarpine was concentration-dependently quenched by alcuronium (pIC 50 ϭ 5.47 Ϯ 0.21; slope factor n H ϭ Ϫ0.59 Ϯ 0.15) to a minimal level of 57 Ϯ 1%, which is not different from the level in the presence of alcuronium alone (unpaired t test, two-tailed, p Ͼ 0.05). According to a partial F-test, the slope factors both for the effect of alcuronium on basal [
35 S]GTP␥S binding and for alcuronium quenching of the pilocarpine signal were not statistically different from unity (p Ͼ 0.05). The slope factor of the atropine curve seemed statistically different from unity (p Ͻ 0.05), but the experiments were not designed to study the steepness of the curves (large concentration steps of 1 log unit).
Results with guinea pig atria suggested that alcuronium affects G protein activation by oxotremorine M and pilocarpine differently. The concentration/effect curves of oxotremorine M in the absence and in the presence of alcuronium are depicted in Fig. 5A . The control curve was characterized by pEC 50 ϭ 7.32 Ϯ 0.11 and E max ϭ 165 Ϯ 2% (n H ϭ 0.76 Ϯ 0.12, n ϭ 3 experiments in 2-fold determinations). Alcuronium at 10 M (n ϭ 3 in 2-fold), 100 M (n ϭ 1 in 6-fold), and 1000 M (n ϭ 1 in 4-fold), induced increasing shifts of the oxotremorine M concentration/effect curve. The maximal effect of oxotremorine M was not affected by alcuronium compared with the control curve (F-test, p Ͼ 0.05). A Schild plot of the curve shifts is depicted in Fig. 5B . The data points fall on a straight line with a slope not different from unity, which indicates a formally competitive interaction between alcuronium and oxotremorine M. The pK A for alcuronium binding to free M 2 receptors amounted to 5.97 Ϯ 0.04 (n ϭ 5). We used oxotremorine M to check whether pilocarpine was still bound under the influence of alcuronium: The effect of oxotremorine M was measured in the presence of a combination of 10 M alcuronium plus 100 M pilocarpine (n ϭ 2 experiments in duplicate determinations). Compared with 10 M alcuronium alone, the presence of pilocarpine induced a further rightward shift of the oxotremorine M concentration/effect relationship (asterisks in Fig. 5A ). Curve fitting to the data points (not shown) suggested a lowered maximum; the corresponding experiments in guinea pig atria had not revealed a diminution of the maximal effect of oxotremorine M in the presence of alcuronium plus pilocarpine (Fig. 3A) . In any case, under both experimental conditions, the combination experiments demonstrate that pilocarpine remained bound in the presence of alcuronium.
Drug Interactions with Labeled Agonist Binding to M 2 Receptors. As mentioned before, the binding experiments of Jakubík et al. (1997) pointed to a modest positive cooperativity between pilocarpine and alcuronium (␤ ϭ 0.37), whereas our functional experiments did not give evidence for an increased potency of pilocarpine in the presence of alcuronium and vice versa. We carried out radioligand binding experiments that were designed in a stepwise approach analogous to that of Jakubík et al. (1997) (Maass and Mohr, 1996) . Fourth, parallel experiments carried out in the presence of a fixed concentration of 0.3 M pilocarpine (Fig. 6B) yielded (eq. 4) the factor of cooperativity between alcuronium and pilocarpine, ␤ ϭ 1.12 Ϯ 0.25. Thus, under the present conditions, there is a nearly neutral coop- erativity between alcuronium and pilocarpine, i.e., the affinity of alcuronium for pilocarpine-occupied receptors (p[␤K A ] ϭ 6.04) is almost the same as in free receptors and vice versa. The parameters characterizing the actions of the test compounds in the three applied assays are compiled in Tables 1  and 2 .
Discussion
The main finding of the present study is that the allosteric modulator alcuronium converts the agonist pilocarpine into an antagonist in intact myocardial tissues. Muscarinic receptors are linked to myocardial contraction force by a complex signaling pathway. To gain insight into the events on the molecular level, we also studied ligand effects on G protein activation in membranes of CHO cells expressing M 2 muscarinic receptors. In both assays, the allosteric agent alcuronium did not affect the potency of the muscarinic agonist pilocarpine but reduced its efficacy. In contrast, with oxotremorine M as the agonist, alcuronium had no effect on the efficacy but reduced the potency. Because both organ bath and in vitro assays yielded corresponding results, we conclude that effects observed in the contracting guinea pig atria seem to result from alcuronium modulation of agonist-mediated G protein activation. Because alcuronium had no effect on G protein activity in wild-type CHO cells but only in CHO cells expressing M 2 receptors, the site of action of alcuronium seems to be the receptor protein.
The distinct effects of alcuronium on pilocarpine and oxotremorine M likely result from structural differences in the respective agonist/receptor-complexes. With respect to the binding of these agonists, the differential interaction of alcuronium with oxotremorine M-and pilocarpine-occupied M 2 receptors has been demonstrated by Jakubík et al. (1997) in radiolabeled antagonist binding experiments. Likewise, the radiolabeled agonist binding experiments of the present study indicate that the affinity of alcuronium for pilocarpineoccupied receptors was markedly higher than for oxotremorine M-occupied receptors (Table 2) . Alcuronium binding to pilocarpine-occupied receptors takes place at concentrations that are close to the concentrations in which alcuronium binds to free M 2 receptors. The slight divergence between the cooperativity factors found by Jakubík et al. (1997) and in this study for the interaction of alcuronium and pilocarpine (␤ ϭ 0.37 and ␤ ϭ 1.12, respectively) may be accounted for by the different assay conditions. Furthermore, Jakubík et al. (1997) , using the antagonist [
3 H]N-methylscopolamine in the presence of GTP, found identical binding affinity for pilocarpine and oxotremorine M (Table 1) , whereas we found ϳ100-fold lower binding affinity of pilocarpine compared with oxotremorine M in the present study, using [ 3 H]oxotremorine M in the absence of GTP (Table 1) (Table 2) are compatible with the notion that alcuronium, in terms of the ternary complex model of allosteric interactions, shows nearly neutral cooperativity with pilocarpine and pronounced negative cooperativity with oxotremorine M.
In line with the binding data, the pilocarpine concentration/effect curves for the negative inotropic effect and for the G protein activation (Figs. 1A and 4A ) remain in the same concentration range when alcuronium is present. In both sets of experiments a shift of the oxotremorine M concentration/ effect curve by pilocarpine (in the presence of alcuronium) provides strong evidence that pilocarpine actually is bound to the receptor and acts as an antagonist (Figs. 3 and 5A asterisks) . The alcuronium-induced reduction of the maximal effect of pilocarpine, therefore, indicates that the formation of ternary complexes is paralleled by a loss of pilocarpine's intrinsic efficacy to induce G protein activation.
Loss of agonist efficacy by formation of ternary complexes has not yet been described in muscarinic receptors. When self-limiting antagonistic actions were observed in organbath experiments with allosteric agents such as gallamine and alkane-bis-ammonium-type compounds and the agonists carbachol, acetylcholine, and oxotremorine (e.g., Lü llmann et al., 1969; Mitchelson, 1975; Clark and Mitchelson, 1976; Trä nkle et al., 1998) , the formation of ternary complexes was the pivotal event but the maximal agonist effects were maintained. Furthermore, allosteric augmentation of the action of acetylcholine , oxotremorine M, and other agonists (Doležal and Tuček, 1998) has been observed without an impairment of the maximal agonist response. Enhanced agonist binding depended on the formation of ternary complexes, without changes in agonist efficacy. In a report on gallamine inhibition of rat myocardial adenylate cyclase by oxotremorine M and the partial agonist N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide, Ehlert (1988b) observed reduction of the maximal effect of N-methyl-N-(1- Pilocarpine is known as a partial agonist in M 2 receptors, whereas oxotremorine M is a full agonist (McKinney et al., 1991; Vogel et al., 1997) . In line with this, pilocarpine reduced the contraction force to CF min ϭ 18 Ϯ 2%, whereas the maximal effect of oxotremorine M (CF min ϭ 7 Ϯ 2%) was more pronounced (p Ͻ 0.002, unpaired t test). In the [ 35 S]GTP␥S binding experiments, the maximal effect of pilocarpine was equal to that of oxotremorine M, but this may be related to the high level of M 2 receptor expression in the transfected CHO cells. Pilocarpine's sensitivity to allosteric modulation of intrinsic efficacy may be accentuated by its partial agonist character. Alcuronium alone had an inverse agonist action in this study similar to that of other muscarinic allosteric agents, e.g., the alkane-bis-ammonium agent hexane-1,6-bis(dimethyl-3Ј-phthalimidopropyl-ammonium bromide) (Hilf and Jakobs, 1992) . Also in cardiomyocytes, alcuronium and gallamine induced an inverse agonist action on G protein activation (Jakubík et al., 1996) similar to that seen with conventional muscarinic antagonists (Jakubík et al., 1995) . Taken together, these prototypal allosteric agents suppress basal G protein activity as inverse agonists and, thus, seem to stabilize preferentially inactive conformations of the muscarinic M 2 receptor. This negative intrinsic activity could have caused the conversion of pilocarpine into an antagonist. As depicted in Fig. 4 , alcuronium suppressed the efficacy of pilocarpine to stimulate G proteins (Fig. 4B , upper curve) in the same concentration range in which it reduced spontaneous receptor activity (Fig. 4B, lower curve) . This finding suggests that alcuronium's binding site, which is located in the entrance of the ligand binding cavity of the receptor protein (Ellis and Seidenberg, 2000; Buller et al., 2002) , has a similar conformation in free and pilocarpineoccupied receptors. One may speculate that pilocarpine-mediated receptor activation goes along with a conformationally malleable receptor state, whereas the rigid alcuronium molecule, upon binding to the allosteric site, may imprint an inactive, more rigid conformation on the pilocarpine/receptor complexes. It is intriguing to speculate that muscarinic allosteric modulators could also induce the reverse action, i.e., preferential allosteric stabilization of active agonist/receptor complexes, thereby, increasing the intrinsic efficacy of an agonist. In case of adenosine A 1 receptors, the 2-amino-3-benzoylthiophene derivative PD 81,723 allosterically enhances agonist action and promotes constitutive receptor activity (e.g., Bruns and Fergus, 1990; Kollias-Baker et al., 1997) .
The allosteric modulation of muscarinic receptor signaling described here differs from a topological and mechanistic point of view from the findings that Litschig et al. (1999) made with another G protein-coupled receptor, i.e., the metabotropic glutamate receptor hmGluR1b. A noncompetitive antagonist was found to inhibit receptor signaling without affecting glutamate binding. In that case, the antagonist did not influence basal receptor signaling activity, and the antagonist action was seen with a variety of agonists. The metabotropic glutamate receptors belong to a subfamily of G protein-coupled receptors that is characterized by a long Nterminal amino acid chain, which contains the agonist binding domain. Possibly, the noncompetitive antagonist binds between the extracellular glutamate binding domain and the transmembrane domain mediating signal transduction (Litschig et al., 1999) . Muscarinic acetylcholine receptors differ such that the agonist binding domain resides in the transmembrane region of the ligand binding cavity and the allosteric site is located above that place, i.e., in the entrance of the ligand binding pocket. Thus, the present study demonstrates another, novel type of interference with G proteincoupled receptor signaling.
A major goal is to identify allosteric agents that modulate agonist and antagonist effects at specific muscarinic receptor subtypes. Here, we demonstrate for the first time that the intrinsic efficacy of muscarinic agonists may be subject to allosteric modulation at the M 2 subtype. Future studies will give more insight in how far this action depends on the type of allosteric agent, the type of orthosteric ligand, and the subtype of muscarinic receptor. 
